American Society of Hematology

Figure 5.

$Figure 5. LCL-161 can enhance the cytotoxic activity of the proteasome inhibitor carfilzomib in ex vivo samples from lymphoma patients with relapsed/refractory and de novo disease. Pure B cell fractions prepared from lymphoma patient biopsy samples were treated for 48 hours in vitro with LCL-161 alone or a combination of LCL-161 and the proteasome inhibitor carfilzomib. Cell-viability readouts were performed using the CellTiter-Glo assay (Promega). Each number on the x-axis represents a unique patient sample. Patient samples are grouped according to histology. All histological diagnoses were performed by the RPCCC Pathology Department. •P < .05, †P < .01, ‡P < .001. FL, follicular lymphoma; MZL, marginal zone lymphoma.$

LCL-161 can enhance the cytotoxic activity of the proteasome inhibitor carfilzomib in ex vivo samples from lymphoma patients with relapsed/refractory and de novo disease. Pure B cell fractions prepared from lymphoma patient biopsy samples were treated for 48 hours in vitro with LCL-161 alone or a combination of LCL-161 and the proteasome inhibitor carfilzomib. Cell-viability readouts were performed using the CellTiter-Glo assay (Promega). Each number on the x-axis represents a unique patient sample. Patient samples are grouped according to histology. All histological diagnoses were performed by the RPCCC Pathology Department. ^•P < .05, †P < .01, ‡P < .001. FL, follicular lymphoma; MZL, marginal zone lymphoma.

This Feature Is Available To Subscribers Only